Scientists test re-engineered immune cells to fight deadly childhood brain cancer
NCT ID NCT04196413
Summary
This early-phase study is testing whether a patient's own immune cells can be modified in a lab to recognize and attack a specific aggressive type of brain or spinal cord tumor. The main goals are to see if these modified cells (called GD2CART) can be reliably made and given safely to children and adults (ages 2-60) with these hard-to-treat cancers. Researchers will also gather early information on whether the treatment helps control the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA OF SPINAL CORD are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lucile Packard Children's Hospital (LPCH)
RECRUITINGStanford, California, 94304, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.